呱柏西利聯合内分泌藥物治療中國人群HR+/HER2-晚期乳腺癌的療效和安全性

The efficacy and safety of palbociclib in combination with hormonal therapy in the treatment of Chinese patients with HR+/HER2-advanced stage breast cancer

目的呱柏西利是一種CDK4/6抑制劑,本文回顧性分析在真實世界中呱柏西利治療澳門地區中國人群HR+/HER2-晚期乳腺癌的療效和安全性。方法連續性收集自2015年4月1日~2017年10月31日在鏡湖醫院就診並確診為HR+/HER2-晚期乳腺癌、接受過或正在接受呱柏西利治療的中國人患者。臨床資料包括患者基線特徵、既往治療等情況,臨床結局指標包括治療緩解情況(RECIST標準)、生存資料和安全性資料。結果共收集46例接受呱柏西利治療的患者。中位年齡為43歲(範圍26歲~76歲)。呱柏西利為晚期一線治療的患者有7例(15.2%)。呱柏西利聯合芳香化酶抑制劑(AI)治療人數為24人,佔52.2%,聯合氟維司群治療人數為21人,佔45.6%。總體疾病控制率73.9%。最常見的不良反應為中性粒細胞減少症,共17例(37.0%)。結論呱柏西利聯合内分泌藥物具有與國外研究結果較為一致的療效和安全性。仍需長期隨訪以獲得生存資料。

Objective Palbociclib is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.The aim of this study is to assess the efficacy and safety of palbociclib in the treatment of patients with HR+/HER2-advanced breast cancer in a Chinese population in Macao.Methods We retrospectively reviewed data of HR+/HER2-advanced breast cancer patients from April 1st 2015 to October 31st 2017 in Kiang Wu Hospital.These patients have currently been receiving or previously received palbociclib treatment.Collected clinical data included baseline characteristics and previous treatments.Outcome variables included cancer remission(RECIST criteria),safety and survival rate.Results 46 patients who received palbociclib were collected in this study with a median age of 43(26-76)years when starting palbociclib treatment.The starting dose of palbociclib was 125mg/day,po.A total of 7(15.2%)patients received palbociclib as first line treatment.The number of patients treated with aromatase inhibitor(AI)or fulvestrant concomitantly was 24(52.2%)and 21(45.6%),respectively.Overall disease control rate was 73.9%.The most common adverse effect was neutropenia,which occurred in 17 patients(37.0%).Conclusion Palbociclib combined with endocrine therapy in Chinese patients with HR+/HER2-advanced breast cancer showed similar outcomes in response and safety rates compared to international trials.Long term follow up is needed to assess the survival rate of patients receiving palbociclib combined with endocrine therapy.